

NEOGEN CORP  
Form 10-Q  
September 30, 2014  
Table of Contents

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended August 31, 2014.**

**or**

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_**

**Commission file number 0-17988**

**Neogen Corporation**

**(Exact name of registrant as specified in its charter)**

**Michigan** **38-2367843**  
**(State or other jurisdiction of** **(IRS Employer**  
**incorporation or organization)** **Identification Number)**

**620 Lesher Place**

**Lansing, Michigan 48912**

**(Address of principal executive offices, including zip code)**

**(517) 372-9200**

**(Registrant's telephone number, including area code)**

**N/A**

**(Former name, former address and former fiscal year, if changed since last report)**

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file reports), and (2) has been subject to such filing requirements for the past 90 days. YES  NO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES  NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer (see definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act):

Large accelerated filer  Accelerated filer

Non-accelerated filer  (Do not check if a smaller reporting company) Smaller Reporting Company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): YES  NO

As of August 31, 2014 there were 36,926,501 shares of Common Stock outstanding.



**Table of Contents**

**NEOGEN CORPORATION AND SUBSIDIARIES**

**TABLE OF CONTENTS**

	<b>Page No.</b>
<b><u>PART I. FINANCIAL INFORMATION</u></b>	
Item 1. <u>Interim Consolidated Financial Statements (unaudited)</u>	2
<u>Consolidated Balance Sheets – August 31, 2014 and May 31, 2014</u>	2
<u>Consolidated Statements of Income – Three months ended August 31, 2014 and 2013</u>	3
<u>Consolidated Statements of Comprehensive Income – Three months ended August 31, 2014 and 2013</u>	4
<u>Consolidated Statement of Equity – Three months ended August 31, 2014</u>	5
<u>Consolidated Statements of Cash Flows – Three months ended August 31, 2014 and 2013</u>	6
<u>Notes to Interim Consolidated Financial Statements – August 31, 2014</u>	7
Item 2. <u>Management’s Discussion and Analysis of Financial Condition and Results of Operations</u>	12
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	16
Item 4. <u>Controls and Procedures</u>	16
<b><u>PART II. OTHER INFORMATION</u></b>	
<u>Item 1. Legal Proceedings</u>	17
<u>Item 6. Exhibits</u>	17
<b><u>SIGNATURES</u></b>	18
<b>CEO Certification</b>	
<b>CFO Certification</b>	
<b>Section 906 Certification</b>	

Table of Contents**PART I FINANCIAL INFORMATION****Item 1. Interim Consolidated Financial Statements****NEOGEN CORPORATION AND SUBSIDIARIES****CONSOLIDATED BALANCE SHEETS***(In thousands, except share and**per share amounts)*

	<b>August 31, 2014 (Unaudited)</b>	<b>May 31, 2014 (Audited)</b>
<b><u>ASSETS</u></b>		
<b>CURRENT ASSETS</b>		
Cash and cash equivalents	\$ 53,457	\$ 40,675
Marketable securities (at fair value, which approximates cost)	34,640	35,821
Accounts receivable, less allowance of \$1,250 and \$1,200	51,689	51,901
Inventories	55,087	51,178
Deferred income taxes	1,680	1,710
Prepaid expenses and other current assets	4,616	7,461
<b>TOTAL CURRENT ASSETS</b>	<b>201,169</b>	<b>188,746</b>
<b>NET PROPERTY AND EQUIPMENT</b>	<b>42,700</b>	<b>41,949</b>
<b>OTHER ASSETS</b>		
Goodwill	68,190	68,190
Other non-amortizable intangible assets	9,682	9,682
Amortizable customer-based intangibles, net of accumulated amortization of \$12,593 and \$11,915 at August 31 and May 31, 2014	24,538	25,230
Other non-current assets, net of accumulated amortization of \$5,467 and \$5,494 at August 31 and May 31, 2014	11,383	11,504
	113,793	114,606
<b>TOTAL ASSETS</b>	<b>\$ 357,662</b>	<b>\$ 345,301</b>
<b><u>LIABILITIES AND EQUITY</u></b>		
<b>CURRENT LIABILITIES</b>		
Accounts payable	\$ 13,002	\$ 13,396
Accrued compensation	4,103	4,357
Income taxes	1,443	0
Other accruals	5,927	7,214
<b>TOTAL CURRENT LIABILITIES</b>	<b>24,475</b>	<b>24,967</b>

Edgar Filing: NEOGEN CORP - Form 10-Q

DEFERRED INCOME TAXES	12,290	12,155
OTHER LONG-TERM LIABILITIES	2,032	1,879
	14,322	14,034
TOTAL LIABILITIES	38,797	39,001
COMMITMENTS AND CONTINGENCIES (note 7)	0	0
EQUITY		
Preferred stock, \$1.00 par value, 100,000 shares authorized, none issued and outstanding		0
Common stock, \$0.16 par value, 60,000,000 shares authorized, 36,926,501 and 36,732,313 shares issued and outstanding at August 31, 2014 and May 31, 2014, respectively.	5,908	5,877
Additional paid-in capital	121,914	118,070
Accumulated other comprehensive income (loss)	152	371
Retained earnings	190,926	182,043
TOTAL NEOGEN CORPORATION AND SUBSIDIARIES STOCKHOLDER S		
EQUITY	318,900	306,361
Noncontrolling interest	(35)	(61)
TOTAL EQUITY	318,865	306,300
TOTAL LIABILITIES AND EQUITY	\$ 357,662	\$ 345,301

See notes to interim consolidated financial statements

Table of Contents

**NEOGEN CORPORATION AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)**

*(In thousands, except per share amounts)*

	<b>Three Months Ended</b>	
	<b>August 31,</b>	
	<b>2014</b>	<b>2013</b>
<b>REVENUES</b>		
Product revenues	\$ 59,255	\$ 51,346
Service revenues	8,344	7,202
Total Revenues	67,599	58,548
<b>COST OF REVENUES</b>		
Cost of product revenues	28,280	23,510
Cost of service revenues	5,243	4,674
Total Cost of Revenues	33,523	28,184
<b>GROSS MARGIN</b>	34,076	30,364
<b>OPERATING EXPENSES</b>		
Sales and marketing	12,220	10,324
General and administrative	6,013	5,536
Research and development	2,404	2,086
	20,637	17,946
<b>OPERATING INCOME</b>	13,439	12,418
<b>OTHER INCOME (EXPENSE)</b>		
Interest income	45	31
Change in purchase consideration	241	0
Other income (expense)	(16)	(552)
	270	(521)
<b>INCOME BEFORE INCOME TAXES</b>	13,709	11,897
<b>PROVISION FOR INCOME TAXES</b>	4,800	4,200
<b>NET INCOME</b>	8,909	7,697
<b>NET LOSS/(INCOME) ATTRIBUTABLE TO NONCONTROLLING INTEREST</b>	(26)	142
<b>NET INCOME ATTRIBUTABLE TO NEOGEN CORPORATION</b>	\$ 8,883	\$ 7,839

NET INCOME ATTRIBUTABLE TO NEOGEN CORPORATION PER SHARE

Edgar Filing: NEOGEN CORP - Form 10-Q

Basic	\$ 0.24	\$ 0.22
Diluted	\$ 0.24	\$ 0.21

See notes to interim consolidated financial statements



Table of Contents

**NEOGEN CORPORATION AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED)**

*(In thousands)*

	<b>Three Months Ended</b>	
	<b>August 31,</b>	
	<b>2014</b>	<b>2013</b>
Net Income	\$ 8,909	\$ 7,697
Other Comprehensive Income (Loss), Net of Tax:		
Currency Translation Adjustments	(219)	330
Comprehensive Income	8,690	8,027
Comprehensive Loss (Income) Attributable to Noncontrolling Interest	(26)	142
Comprehensive Income Attributable to Neogen Corporation	\$ 8,664	\$ 8,169

See notes to interim consolidated financial statements

Table of Contents

**NEOGEN CORPORATION AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENT OF EQUITY (UNAUDITED)**

*(In thousands)*

	Common Stock		Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)		Retained Earnings	Non- controlling Interest	Total
	Shares	Amount						
Balance, June 1, 2014	36,732	\$ 5,877	\$ 118,070	\$ 371	\$ 182,043		(\$61)	\$ 306,300
Issuance of shares of common stock under equity compensation plans, and share based compensation	186	30	3,521					3,551
Issuance of shares under employee stock purchase plan	9	1	323					324
Comprehensive income:								
Net income (loss) for the three months ended August 31, 2014					8,883		26	8,909
Other comprehensive loss				(219)				(\$219)
Balance, August 31, 2014	36,927	\$ 5,908	\$ 121,914	\$ 152	\$ 190,926		(\$35)	\$ 318,865

See notes to interim consolidated financial statements

Table of Contents

**NEOGEN CORPORATION AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)**

*(In thousands)*

	<b>Three Months Ended</b>	
	<b>August 31,</b>	
	<b>2014</b>	<b>2013</b>
<b>CASH FLOWS FROM OPERATING ACTIVITIES:</b>		
Net Income	\$ 8,909	\$ 7,697
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	2,515	2,029
Share based compensation	907	789
Excess income tax benefit from the exercise of stock options	(865)	(1,585)
Changes in operating assets and liabilities, net of business acquisitions:		
Accounts receivable	155	(4,069)
Inventories	(3,933)	(3,207)
Prepaid expenses and other current assets	2,843	(96)
Accounts payable, accruals and other	(106)	3,950
<b>NET CASH PROVIDED BY OPERATING ACTIVITIES</b>	<b>10,425</b>	<b>5,508</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>		
Purchases of property and equipment and other noncurrent assets	(2,511)	(2,041)
Proceeds from the sale of marketable securities	22,946	25,732
Purchases of marketable securities	(21,765)	(31,162)
Business acquisitions, net of cash acquired	0	(10,012)
<b>NET CASH USED IN INVESTING ACTIVITIES</b>	<b>(1,330)</b>	<b>(17,483)</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>		
Exercise of stock options	2,933	3,806
Excess income tax benefit from the exercise of stock options	865	1,585
Increase in other long-term liabilities	0	56
<b>NET CASH PROVIDED BY FINANCING ACTIVITIES</b>	<b>3,798</b>	<b>5,447</b>
<b>EFFECT OF EXCHANGE RATE ON CASH</b>	<b>(111)</b>	<b>104</b>
<b>NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b>	<b>12,782</b>	<b>(6,424)</b>
<b>CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b>	<b>40,675</b>	<b>50,032</b>
<b>CASH AND CASH EQUIVALENTS AT END OF PERIOD</b>	<b>\$ 53,457</b>	<b>\$ 43,608</b>

See notes to interim consolidated financial statements



Table of Contents**NEOGEN CORPORATION AND SUBSIDIARIES****NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)****1. BASIS OF PRESENTATION**

The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (generally accepted accounting principles) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation have been included. The results of operations for the three month period ended August 31, 2014 are not necessarily indicative of the results to be expected for the fiscal year ending May 31, 2015. For more complete financial information, these consolidated financial statements should be read in conjunction with the May 31, 2014 audited consolidated financial statements and the notes thereto included in the Company's annual report on Form 10-K for the year ended May 31, 2014.

**2. INVENTORIES**

Inventories are stated at the lower of cost, determined on the first-in, first-out method, or market. The components of inventories follow:

	<b>August 31, 2014</b>	<b>May 31, 2014</b>
	<i>(In thousands)</i>	
Raw Materials	\$ 22,121	\$ 21,515
Work-in-process	4,206	3,681
Finished and purchased goods	28,760	25,982
	\$ 55,087	\$ 51,178

**3. NET INCOME PER SHARE**

The calculation of net income per share attributable to Neogen Corporation follows:

	<b>Three Months Ended</b>	
	<b>August 31,</b>	<b>2013</b>
	<b>2014</b>	<b>2013</b>
	<i>(In thousands, except per share amounts)</i>	
Numerator for basic and diluted net income per share:		
Net Income attributable to Neogen shareholders	\$ 8,883	\$ 7,839
Denominator:		
Denominator for basic net income per share:		

Edgar Filing: NEOGEN CORP - Form 10-Q

Weighted average shares	36,776	36,159
Effect of dilutive stock options and warrants	514	858
Denominator for diluted net income per share	37,290	37,017
Net income attributable to Neogen Corporation		
per share:		
Basic	\$ 0.24	\$ 0.22
Diluted	\$ 0.24	\$ 0.21

The Board of Directors declared a 3 for 2 stock split effective October 31, 2013. All share and per share amounts in this Form 10-Q reflect amounts as if the split took place at the beginning of the periods presented

**Table of Contents****4. SEGMENT INFORMATION**

The Company has two reportable segments: Food Safety and Animal Safety. The Food Safety segment produces and markets diagnostic test kits and related products used by food producers and processors to detect harmful natural toxins, foodborne bacteria, allergens and levels of general sanitation. The Animal Safety segment is primarily engaged in the production and marketing of products dedicated to animal health, including a complete line of consumable products marketed to veterinarians and animal health product distributors; the segment also provides genetic identification services. Additionally, Animal Safety produces and markets rodenticides, disinfectants and insecticides to assist in the control of rodents and disease in and around agricultural, food production and other facilities.

Segment information as of and for the three months ended August 31, 2014 and 2013 follows:

	<b>Food Safety</b>	<b>Animal Safety</b>	<b>Corporate and Eliminations (1)</b>	<b>Total</b>
	<i>(In thousands)</i>			
<b>Fiscal 2015</b>				
Product revenues to external customers	\$ 29,093	\$ 30,162	\$	\$ 59,255
Service revenues to external customers	1,870	6,474	0	8,344
Total revenues to external customers	30,963	36,636	0	67,599
Operating income (loss)	7,515	6,705	(781)	13,439
Total assets	103,637	176,419	77,606	357,662
<b>Fiscal 2014</b>				
Product revenues to external customers	\$ 28,554	\$ 22,792	\$ 0	\$ 51,346
Service revenues to external customers	1,444	5,758	0	7,202
Total revenues to external customers	29,998	28,550	0	58,548
Operating income (loss)	8,701	4,420	(703)	12,418
Total assets	98,062	136,687	73,388	308,137

- (1) Includes corporate assets, consisting principally of cash and cash equivalents, marketable securities, deferred assets and overhead expenses not allocated to specific business segments. Also includes the elimination of intersegment transactions.

**Table of Contents****5. EQUITY COMPENSATION PLANS**

Options are generally granted under the employee and director stock option plan for five-year periods and become exercisable in equal annual installments during that period. Certain non-qualified options are granted for ten-year periods. A summary of stock option activity during the three months ended August 31, 2014 follows:

	<b>Shares</b>	<b>Weighted-Average Exercise Price</b>
Options outstanding at June 1, 2014	1,869,000	\$ 25.69
Granted	0	0
Exercised	191,000	14.85
Forfeited	27,000	33.95
Options outstanding at August 31, 2014	1,651,000	26.82

During the three month periods ended August 31, 2014 and 2013, the Company recorded \$907,000 and \$789,000 and of compensation expense related to its share-based awards.

The weighted-average fair value of stock options granted during fiscal 2014, estimated on the date of grant using the Black-Scholes option pricing model was \$9.87, per option. No options were granted in the first quarter of fiscal 2015. The fair value of stock options granted in fiscal 2014 was estimated using the following weighted-average assumptions.

	<b>FY2014</b>
Risk-free interest rate	0.8%
Expected dividend yield	0%
Expected stock price volatility	33.1%
Expected option life	4.0 years

The Company has an Employee Stock Purchase plan that provides for employee stock purchases at a 5% discount to market price. The discount is recorded in administrative expense as of the date of purchase.

**6. NEW ACCOUNTING PRONOUNCEMENTS**

In February 2013, the FASB further amended ASC 220, Comprehensive Income, with ASU 2013-02, Comprehensive Income (Topic 220) Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income (amended ASC 220), which was designed to improve the reporting of reclassifications out of accumulated other comprehensive income by requiring an entity to present the effect of significant reclassifications out of accumulated other comprehensive income on the respective lines of net income. The impact of adopting amended ASC 220 did not have a material impact on the consolidated financial statements and therefore has not been disclosed in the fiscal 2015 first quarter Form 10-Q.



---

**Table of Contents****7. BUSINESS AND PRODUCT LINE ACQUISITIONS**

The consolidated statements of income reflect the results of operations for business acquisitions since the respective dates of purchase. All are accounted for using the acquisition method.

On July 1, 2013, the Company acquired the assets of SyrVet Inc., a veterinary business based in Waukee, Iowa. SyrVet offered a product line similar to Neogen's Ideal Instruments line of veterinary instruments with a strong presence in Mexico and Latin America. Consideration for the purchase was \$10,012,000 in cash and up to \$1,500,000 of a contingent consideration liability, due at the end of the first year, based on an excess net sales formula. The final purchase price allocation, based upon the fair value of these assets determined using the income approach, included accounts receivable of \$747,000, net inventory of \$2,195,000, property and equipment of \$556,000, current liabilities of \$226,000, contingent consideration liabilities of \$930,000, non-amortizable trademarks of \$790,000, intangible assets of \$4,810,000 (with an estimated life of 15 years) and the remainder to goodwill (deductible for tax purposes). These values are Level 3 fair value measurements. This business has been relocated to Lexington, Kentucky and integrated with the Company's current operations there, reporting within the Animal Safety segment. In August 2014, the company paid \$689,000 to the former owner for contingent consideration; the remaining \$241,000 of the accrual was reversed to Other Income.

On November 1, 2013, the Company acquired the assets of Prima Tech Incorporated, a veterinary instrument company based in Kenansville, North Carolina. Prima Tech manufactures devices used by farmers, ranchers, and veterinarians to inject animals, provide topical applications, and to use for oral administration. Prima Tech is also a supplier of products used in artificial insemination in the swine industry. Consideration for the purchase was \$12,068,000 in cash and up to \$600,000 of contingent consideration, due at the end of the first year, based on an excess net sales formula. The Company has estimated the contingent consideration liability to be \$146,000 based on forecasted sales. The final purchase price allocation, based upon the fair value of these assets determined using the income approach, included accounts receivable of \$963,000, net inventory of \$2,796,000, property and equipment of \$1,653,000, prepaid assets of \$8,000, current liabilities of \$1,840,000, contingent consideration liabilities of \$146,000, non-amortizable trademarks of \$1,500,000, intangible assets of \$4,400,000 (with an estimated life of 5-15 years) and the remainder to goodwill (deductible for tax purposes). These values are Level 3 fair value measurements. This business will continue to operate in its current location and reports within the Animal Safety segment.

On January 2, 2014, the Company acquired all of the stock of Chem-Tech Ltd., a pest control manufacturing and distribution business located in Pleasantville, Iowa. Consideration for the purchase was \$17,185,000 in cash and up to \$1,000,000 of a contingent consideration liability, due at the end of the first year, based on an excess sales formula. The Company has estimated the contingent consideration liability to be \$400,000, based on forecasted sales. The preliminary purchase price allocation included accounts receivable of \$380,000, net inventory of \$4,096,000, prepaid assets of \$225,000, property and equipment of \$682,000, current liabilities of \$184,000, contingent consideration liabilities of \$400,000, non-amortizable trademarks of \$662,000, intangible assets of \$7,536,000 (with an estimated life of 15 years) and the remainder to goodwill (deductible for tax purposes). These values are Level 3 fair value measurements. This business will continue to operate in its current location and reports within the Animal Safety segment.

Goodwill recognized in the acquisitions discussed above relates primarily to enhancing the Company's strategic platform for the expansion of available product offerings.

**Table of Contents**

**8. LONG TERM DEBT**

The Company has a financing agreement with a bank providing for an unsecured revolving line of credit of \$12,000,000, which matures on September 1, 2017. There were no advances against this line of credit during fiscal 2015 and fiscal 2014 and no balance outstanding at August 31, 2014. Interest is at LIBOR plus 100 basis points (rate under the terms of the agreement was 1.16% at August 31, 2014). Financial covenants include maintaining specified levels of tangible net worth, debt service coverage, and funded debt to EBITDA, each of which the Company was in compliance with at August 31, 2014.

**9. COMMITMENTS AND CONTINGENCIES**

The Company is involved in environmental remediation and monitoring activities at its Randolph, Wisconsin manufacturing facility and accrues for related costs when such costs are determined to be probable and estimable. The Company is currently expensing annual costs of remediation, which have ranged from \$47,000 to \$79,000 per year over the past five years. The Company's estimated liability for these costs of \$916,000 at August 31, 2014 and May 31, 2014, measured on an undiscounted basis over an estimated period of 15 years, is recorded within other long-term liabilities in the consolidated balance sheet.

The Company is subject to certain legal and other proceedings in the normal course of business that, in the opinion of management, should not have a material effect on its future results of operations or financial position.

**10. STOCK PURCHASE**

In December 2008, the Company's Board of Directors authorized a program to purchase, subject to market conditions, up to 1,125,000 shares of the Company's common stock. As of August 31, 2014, 112,026 cumulative shares had been purchased in negotiated and open market transactions for a total price, including commissions, of approximately \$923,000. Shares purchased under the program were retired. There have been no purchases in fiscal 2015 and there were none in fiscal 2014.

**Table of Contents**

**PART I FINANCIAL INFORMATION**

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations**

The information in this Management's Discussion and Analysis of Financial Condition and Results of Operations contains both historical financial information and forward-looking statements. Neogen does not provide forecasts of future performance. While management is optimistic about the Company's long-term prospects, historical financial information may not be indicative of future financial performance.

**Safe Harbor and Forward-Looking Statements**

Forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, are made throughout this Quarterly Report on Form 10-Q. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward looking statements. Without limiting the foregoing, the words believes, anticipates, plans, expects, seeks, estimates, and similar expressions are intended to identify forward-looking statements. There are a number of important factors, including competition, recruitment and dependence on key employees, impact of weather on agriculture and food production, identification and integration of acquisitions, research and development risks, patent and trade secret protection, government regulation and other risks detailed from time to time in the Company's reports on file at the Securities and Exchange Commission, that could cause Neogen Corporation's results to differ materially from those indicated by such forward-looking statements, including those detailed in this Management's Discussion and Analysis of Financial Condition and Results of Operations.

In addition, any forward-looking statements represent management's views only as of the day this Quarterly Report on Form 10-Q was first filed with the Securities and Exchange Commission and should not be relied upon as representing management's views as of any subsequent date. While management may elect to update forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if its views change.

**Critical Accounting Policies and Estimates**

The discussion and analysis of the Company's financial condition and results of operations are based on the consolidated financial statements that have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires that management make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an ongoing basis, management evaluates the estimates, including those related to receivable allowances, inventories, accruals, goodwill and other intangible assets. These estimates are based on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There were no significant changes to our contractual obligations or contingent liabilities and commitments disclosed in the Company's Annual Report on Form 10-K for the fiscal year ended May 31, 2014.

There have been no material changes to the critical accounting policies and estimates disclosed in the Company's Annual Report on Form 10-K for the fiscal year ended May 31, 2014.



---

**Table of Contents**

**Executive Overview**

Neogen Corporation revenues for the quarter ended August 31, 2014 were \$67.6 million, an increase of \$9.1 million, or 15.5%, compared to the first quarter of the prior year. Net income attributable to Neogen for the first quarter increased 13.3% to \$8.9 million, or \$0.24 per fully diluted share, compared to \$7.8 million, or \$0.21 per fully diluted share, in the first quarter of fiscal 2014.

Food Safety revenues increased by 3.2% and Animal Safety revenues increased by 28.3%. Sales from recent acquisitions contributed \$8.5 million towards revenues in the current quarter. These acquisitions were Syrvet in July 2013, Prima Tech in November 2013 and Chem-Tech in January 2014.

International sales were 37.0% of total sales in the first quarter, compared to 42.3% in the prior year. Revenues from Chem-Tech were all domestic sales, which contributed to the decline of international sales as a percentage of the total; there was also a shortfall in international sales of drug residue test kits due to order timing of a large international distributor. In the first quarter of fiscal 2014, Neogen Europe sales increased 8.6%, led by higher genomics and allergen sales, which more than offset lower sales of mycotoxin and speciation tests. Neogen Latinoamerica's revenues increased 77.4%, led by higher sales of cleaners and disinfectants and veterinary instruments to customers in Mexico and Central America. Neogen do Brasil revenues decreased 9.0% in the first quarter of fiscal 2014 compared to the prior year. In Brazil, sales of Food Safety products increased 11.6%, but this was offset by declines in sales of cleaners and disinfectants, due to order timing, and genomics, due to a large one-time research project in the first quarter of the prior year.

Service revenue from DNA testing was \$8.3 million, an increase of \$1.1 million, or 15.9%, compared to the same period in the prior year. This increase resulted from strong sales to European customers, a significant chicken genotyping research project, and growth within the porcine market.

Consolidated gross margins were 50.4% in the first quarter of fiscal 2015, a decrease of 150 basis points compared to the same period in the prior fiscal year, but up 280 basis points over the last quarter of the 2014 fiscal year. The decline in gross margin compared to the prior year is primarily due to the shift in revenues from the Food Safety segment to the Animal Safety segment, which has lower gross margins. Animal Safety sales, as a percentage of the total, increased from 48.8% in the first quarter of fiscal 2014 to 54.2% in the current fiscal quarter. The gross margin improvement compared to the fourth quarter of fiscal 2014 was due to improved product mix and efficiencies within the Animal Safety segment.

Operating expenses increased 15.0% for the first quarter, in line with the revenue increase. Sales and marketing expenses rose by 18.4%, primarily reflecting the impact of new personnel additions in the past year, and increased shipping expenses. General and administrative expenses rose by 8.6%, due to higher amortization expenses resulting from the prior year's acquisitions and increased stock option expense. Research and development expenses were up 15.2%, reflecting higher outside services and costs incurred in scaling up new products for manufacturing.

Other Income in the fiscal 2015 first quarter included \$241,000 due to an overaccrual of contingent consideration related to the Syrvet acquisition. In the first quarter of fiscal 2014, \$592,000 of expense related to currency translations was recorded in other income/expense.

**Table of Contents****Revenues**

	<b>Three Months ended August 31, 2014</b>			
	<b>2014</b>	<b>2013</b>	<b>Increase/ (Decrease)</b>	<b>%</b>
	<i>(In thousands)</i>			
<b><u>Food Safety</u></b>				
Natural Toxins, Allergens & Drug Residues	\$ 15,440	\$ 15,875	\$ (435)	(2.7%)
Bacteria & General Sanitation	6,254	6,071	183	3.0%
Dehydrated Culture Media & Other	9,269	8,052	1,217	15.1%
	\$ 30,963	\$ 29,998	\$ 965	3.2%
<b><u>Animal Safety</u></b>				
Life Sciences	\$ 2,345	\$ 1,918	\$ 427	22.3%
Veterinary Instruments & Disposables	7,520	4,832	2,688	55.6%
Animal Care & Other	7,589	8,335	(746)	(9.0%)
Rodenticides, Disinfectants & Insecticides	12,708	7,707	5,001	64.9%
DNA Testing Service	6,474	5,758	716	12.4%
	\$ 36,636	\$ 28,550	\$ 8,086	28.3%
<b>Total Revenues</b>	<b>\$ 67,599</b>	<b>\$ 58,548</b>	<b>\$ 9,051</b>	<b>15.5%</b>

The Company's Food Safety segment revenues were \$31.0 million for the first quarter ended August 31, 2014, an increase of 3.2% compared to the same period in the prior year. Natural Toxins, Allergens and Drug Residues revenues decreased 2.7%. Within this category, sales of natural toxins decreased 4.1%, caused by high demand in the prior year due to aflatoxin outbreaks, primarily in Eastern Europe. Crops in the current year have been relatively clean, with no spikes in testing. Drug Residues revenues are down 12.0% in the first quarter due to a combination of order timing by a large international distributor and lower sales to customers in Eastern Europe due to delays in the launch of a new product required by legislation in that region. Offsetting these decreases, sales of Allergens increased 11.5%, due to increased market demand, particularly for milk and gliadin (gluten) tests. Within this category, meat speciation kits declined against tough comparisons in the prior year created by the horse meat scandal in Europe, which was uncovered in January 2013.

Bacterial and General Sanitation sales increased 3.0% in the first quarter compared to the same period in the prior year. The increase in this category was led by sales of ampoule media and filters, as the Company continues to increase market share in this product line, particularly in the beverage industry. Dehydrated Culture Media and Other sales increased 15.1% over the prior year. This category was led by increases in genomics revenues to European customers and sales of animal safety products to customers in Mexico and Central America; a number of customers were transferred to Neogen Latinoamerica at the beginning of fiscal 2015 to more directly serve customers in those areas.

Animal Safety segment revenues were \$36.6 million, an increase of 28.3% compared to the first quarter in the prior year. Life Sciences sales increased 22.3%, led by forensic kit sales to commercial testing labs to meet new testing requirements in Brazil for commercial drivers. Revenues of Veterinary Instruments and Disposables increased 55.6%, led by significant contributions from the Syrvet and Prima Tech acquisitions. Excluding those revenues, the increase

in the first quarter compared to the same period in the prior year was 10.9%. Organic growth in this category was led by sales of detectable needles, which continue to be a strong product, and syringe and needle sales to new private label and OEM customers. This growth was partially offset by a decline in disposables sales, due to order timing, and the transfer of some customers to Neogen Latinoamerica.

Animal Care and Other sales decreased 9.0% in the first quarter of fiscal 2015 compared to the first quarter of fiscal 2014. Within this category in the prior year, the Company recorded strong sales of a wound care product caused by a supply disruption in the market. This product was available for sale from all competitors in the current quarter. Additionally, a distributed antibiotic was discontinued by the manufacturer towards the end of fiscal 2014, so there are no comparable sales in the current quarter. Rodenticides, Insecticides and Disinfectants sales had an increase of 64.9% in the first quarter compared to the prior year, with a contribution of \$5.1 million in revenues from Chem-Tech. Rodenticide sales increased 38.7% primarily due to a vole outbreak in the western U.S. Offsetting this increase, Cleaners & Disinfectants revenues decreased 31.0%. Order timing and strong prior year sales due to international disease outbreaks contributed to the decrease in the current quarter.

DNA Testing revenues increased by 12.4% for the quarter compared to the prior year. The increase was led by a significant chicken genotyping research project and strong sales into the porcine market.

**Table of Contents**

**Financial Condition and Liquidity**

The overall cash, cash equivalents and marketable securities position of the Company was \$88,097,000 at August 31, 2014, compared to \$76,496,000 at May 31, 2014. Approximately \$10,425,000 in cash was generated from operations during the first three months of fiscal 2015. Net cash proceeds of \$2,933,000 were realized from the exercise of stock options and issuance of shares under the Company's Employee Stock Purchase Plan during the first three months of fiscal 2015. The Company spent \$2,511,000 for property, equipment and other non-current assets in the first three months of fiscal 2015.

Accounts receivable decreased by \$212,000 from May 31, 2014, while inventories rose by \$3,909,000, or 7.6%, due primarily to increases in the Animal Safety distribution business. Company management has programs in place at each operation to improve the Company's inventory turns during fiscal 2015.

Inflation and changing prices are not expected to have a material effect on operations, as management believes it will continue to be successful in offsetting increased input costs with price increases and/or cost efficiencies

Management believes that the Company's existing cash and marketable securities balances at August 31, 2014, along with available borrowings under its credit facility and cash expected to be generated from future operations, will be sufficient to fund activities for the foreseeable future. However, existing cash and borrowing capacity may not be sufficient to meet the Company's cash requirements to commercialize products currently under development or its plans to acquire other organizations, technologies or products that fit within the Company's mission statement. Accordingly, the Company may choose to issue equity securities or enter into other financing arrangements for a portion of its future financing needs.



**Table of Contents**

**PART I FINANCIAL INFORMATION**

**Item 3. Quantitative and Qualitative Disclosures About Market Risk**

The Company has interest rate and foreign exchange rate risk exposure. It has no long-term fixed rate investments or borrowings. Primary interest rate risk is due to potential fluctuations in interest rates for variable rate borrowings; currently, there are no short-term borrowings outstanding and there were none during the quarter.

Foreign exchange risk exposure arises because the Company markets and sells its products throughout the world. The Company also could be affected by weak economic conditions in foreign markets that could reduce demand for its products. Additionally, revenues in certain foreign countries as well as certain expenses related to those revenues are transacted in currencies other than the U.S. Dollar. The Company's operating results are primarily exposed to changes in exchange rates between the U.S. Dollar, the British Pound Sterling and the Euro. When the U.S. Dollar weakens against foreign currencies, the dollar value of revenues denominated in foreign currencies increases. When the U.S. Dollar strengthens, the opposite situation occurs. Additionally, previously recognized revenues in the course of collection can be affected positively or negatively by changes in exchange rates. The Company uses derivative financial instruments to help manage the economic impact of fluctuations in certain currency exchange rates. These contracts are adjusted to fair value through earnings.

Neogen has assets, liabilities and operations outside of the United States, located in Scotland, Brazil and Mexico, where the functional currency is the British Pound Sterling, Brazilian Real and Mexican Peso, respectively. The Company's investments in foreign subsidiaries are considered to be long-term.

**PART I FINANCIAL INFORMATION**

**Item 4. Controls and Procedures**

**Evaluation of Disclosure Controls and Procedures**

An evaluation of the effectiveness of the design and operation of the Company's disclosure controls and procedures as of August 31, 2014 was carried out under the supervision and with the participation of the Company's management, including the Chairman & Chief Executive Officer and the Vice President & Chief Financial Officer (the Certifying Officers). Based on the evaluation, the Certifying Officers concluded that the Company's disclosure controls and procedures are effective.

**Changes in Internal Controls Over Financial Reporting**

There was no change to the Company's internal control over financial reporting during the quarter ended August 31, 2014 that materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

**Table of Contents**

**PART II OTHER INFORMATION**

**Item 1. Legal Proceedings**

The Company is subject to certain legal and other proceedings in the normal course of business. In the opinion of management, the outcomes of these matters are not expected to have a material effect on its future results of operations or financial position.

**Item 6. Exhibits**

(a) Exhibit Index

31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a).
31.2	Certification of Chief Financial Officer pursuant to Rule 13a 14(a).
32	Certification pursuant to 18 U.S.C. section 1350
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

**Items 1A, 2, 3, 4, and 5 are not applicable or removed or reserved and have been omitted.**

Table of Contents

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

NEOGEN CORPORATION  
*(Registrant)*

Dated: September 30, 2014

/s/ James L. Herbert  
James L. Herbert  
Chairman & Chief Executive Officer  
(Principal Executive Officer)

Dated: September 30, 2014

/s/ Steven J. Quinlan  
Steven J. Quinlan  
Vice President & Chief Financial Officer  
(Principal Financial Officer and Principal Accounting Officer)